A Cure For Back Pain? Phase II Clinical Trials Begin For Promising Drug Candidate

Dr. Jason Lipetz, MD, Physiatrist & Head of Spine Medicine at Northwell Health, was recently interviewed by Benzinga. Dr. Lipetz is currently assisting BioRestorative Therapies, Inc BRTX in phase 2 trials of a novel therapy for degenerative disc disease, BRTX-100.

BioRestorative Therapies is a biotechnology company focused on creating stem cell therapies to address unmet needs. The company’s technology harnesses the power of a patient's own regenerative potential to aid in conditions from back pain to metabolic disease.

BRTX-100 is a novel treatment for cLDD – chronic lumbar disc disease – a debilitating condition affecting millions across the globe. Marked by back pain, stiffness and restricted movement, cLDD is a serious condition that greatly impacts a person’s quality of life. BioRestorative Therapies reports that BRTX-100 has shown promising results in using the body’s own power to heal itself.

Watch the full interview here:

Featured photo by Louis Reed on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechInterviewGeneralBioRestorative Therapies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!